India, Nov. 27 -- Ceremorphic Life Sciences division will help transform the entire drug discovery and development process. It will have access to Ceremorphic's own proprietary analog and AI technology platform that will allow its team of biology and chemistry experts to begin developing drugs at a pace unprecedented in the pharmaceutical industry.

Its new platform, BioCompDiscoverX, is based on Ceremorphic's own proprietary patent pending technologies and includes a hardware-software solution leveraging its own advanced silicon technology.

Dr. Venkat Mattela, Founder& CEO, Ceremorphic, tells us more. Excerpts from an interview:

DQ: Please elaborate on Ceremorphic's venture into the life sciences vertical, and the reason behind it.